JP Morgan Chase’s AMAG Pharmaceuticals AMAG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-82,705
| Closed | -$767K | – | 6163 |
|
|
2020
Q3 | $767K | Sell |
82,705
-6,508
| -7% | -$61.9K | ﹤0.01% | 3781 |
|
|
2020
Q2 | $683K | Sell |
89,213
-3,457
| -4% | -$26.5K | ﹤0.01% | 3722 |
|
|
2020
Q1 | $572K | Sell |
92,670
-32,105
| -26% | -$283K | ﹤0.01% | 3753 |
|
|
2019
Q4 | $1.52M | Sell |
124,775
-9,377
| -7% | -$102K | ﹤0.01% | 3579 |
|
|
2019
Q3 | $1.55M | Buy |
134,152
+3,707
| +3% | +$39K | ﹤0.01% | 3572 |
|
|
2019
Q2 | $1.24M | Sell |
130,445
-2,466
| -2% | -$26.6K | ﹤0.01% | 3708 |
|
|
2019
Q1 | $1.71M | Sell |
132,911
-846,765
| -86% | -$12.6M | ﹤0.01% | 3440 |
|
|
2018
Q4 | $14.9M | Sell |
979,676
-62,708
| -6% | -$1.19M | ﹤0.01% | 1708 |
|
|
2018
Q3 | $20.8M | Sell |
1,042,384
-359,792
| -26% | -$8.19M | ﹤0.01% | 1626 |
|
|
2018
Q2 | $27.3M | Buy |
1,402,176
+281,360
| +25% | +$6.22M | 0.01% | 1357 |
|
|
2018
Q1 | $22.6M | Buy |
1,120,816
+242,435
| +28% | +$4.1M | ﹤0.01% | 1430 |
|
|
2017
Q4 | $11.6M | Buy |
878,381
+332,215
| +61% | +$5.01M | ﹤0.01% | 2003 |
|
|
2017
Q3 | $9.7M | Sell |
546,166
-23,048
| -4% | -$430K | ﹤0.01% | 2012 |
|
|
2017
Q2 | $10.5M | Sell |
569,214
-311,920
| -35% | -$6.18M | ﹤0.01% | 1937 |
|
|
2017
Q1 | $19.9M | Buy |
881,134
+29,046
| +3% | +$695K | ﹤0.01% | 1476 |
|
|
2016
Q4 | $29.7M | Buy |
852,088
+443,841
| +109% | +$13.3M | 0.01% | 1209 |
|
|
2016
Q3 | $10M | Sell |
408,247
-28,072
| -6% | -$702K | ﹤0.01% | 1790 |
|
|
2016
Q2 | $10.4M | Buy |
436,319
+142,084
| +48% | +$3.26M | ﹤0.01% | 1806 |
|
|
2016
Q1 | $6.88M | Buy |
294,235
+14,488
| +5% | +$344K | ﹤0.01% | 2006 |
|
|
2015
Q4 | $8.45M | Sell |
279,747
-22,341
| -7% | -$722K | ﹤0.01% | 1923 |
|
|
2015
Q3 | $12M | Buy |
302,088
+82,955
| +38% | +$5.15M | ﹤0.01% | 1622 |
|
|
2015
Q2 | $15.1M | Buy |
219,133
+2,344
| +1% | +$147K | ﹤0.01% | 1602 |
|
|
2015
Q1 | $11.8M | Buy |
216,789
+181,000
| +506% | +$8.63M | ﹤0.01% | 1792 |
|
|
2014
Q4 | $1.52M | Sell |
35,789
-106,578
| -75% | -$3.85M | ﹤0.01% | 3114 |
|
|
2014
Q3 | $4.54M | Sell |
142,367
-100,138
| -41% | -$2.14M | ﹤0.01% | 2427 |
|
|
2014
Q2 | $5.03M | Sell |
242,505
-93,800
| -28% | -$1.73M | ﹤0.01% | 2066 |
|
|
2014
Q1 | $6.51M | Sell |
336,305
-717,463
| -68% | -$15.2M | ﹤0.01% | 1941 |
|
|
2013
Q4 | $25.6M | Buy |
1,053,768
+104,515
| +11% | +$2.46M | 0.01% | 1187 |
|
|
2013
Q3 | $20.4M | Buy |
949,253
+132,733
| +16% | +$3.14M | 0.01% | 1317 |
|
|
2013
Q2 | $18.2M | Buy |
+816,520
| New | +$18M | 0.01% | 1313 |
|
JP Morgan Chase's AMAG Position: Q4 2020 in Review
JP Morgan Chase sold out of AMAG Pharmaceuticals (AMAG) in Q4 2020, closing a stake of 82,705 shares — an estimated $767K sold.
JP Morgan Chase first reported a position in AMAG in Q2 2013 and held it in 30 quarters. The position peaked at $29.7M in Q4 2016. 1 fund tracked by Wall St. Rank holds AMAG as of Q4 2020.
- JP Morgan Chase reported no remaining AMAG Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
- JP Morgan Chase sold 82,705 AMAG Pharmaceuticals shares in Q4 2020, an estimated $767K.
- JP Morgan Chase first reported a position in AMAG Pharmaceuticals in Q2 2013 and held it in 30 quarters.
- JP Morgan Chase's AMAG Pharmaceuticals position peaked at $29.7M in Q4 2016.
- 1 fund tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2020.
Based on JP Morgan Chase's 13F filing for Q4 2020, filed 11 Feb 2021.